the dust wont settle for months. We imminently await Parson`s new expectations in damages decision. Nothing has really changed.
so Siga is fined for breach of contract. Given that Pharmathene hasn't contributed a cent as part of their contractual obligations, given Siga's bridge-loan repayment 7 yrs ago, will Parsons have to give this aspect of the contract consideration under expectation damages?
My impression is that this recent ruling has created more of a quagmire than it was previously. How long will Parsons rewarding expectation damages take? Another 3-6 months?
At this point Siga, with Chimerix waiting in the wings, isn`t even sure of further orders once this current $300m order is fulfilled.
"On May 21, 2013, our 2010 Equity Incentive Plan (the "2010 Plan") was amended to, among other things, increase the aggregate number of shares of common stock authorized for issuance under the 2010 Plan by 5,100,000 shares" this was just part of employee incentive plan. Kinda sneaky to squeeze it in just bfr. the long weekend. Like you, I have a strong beaver hunch that this may lead to dancing with a buyout partner within the 30 day period. Would have been nicer if these board members had voted shareholders an additional $40M incentive, instead of exclusively for themselves.
Pfizer with a Zyvox expiry, Cubist with a Tedizolid patent combo extension or grand daddy Bayer with an Asian mail order bride? Ted must be blushing with all this current dating interest in him.
never mind it was just turbulence from someone throwing a big cubist of dry ice into the pond. Made the water pfizzle and covered the surface with fog.
Should never use margarine on speculative stocks. Always use butter. Too much volatility can easily turn U into dry toast without a spread.
...it was a rice paddy coy pond built on a mtn slide. Prone to such mishaps during quakes. Godzilla lives there what can one expect?
The MM here likes nothing better than a pretense to create volatility. My order got filled.
I guess it's my ST memory, or early onset dementia...my May 8/13 post, "TSRX is working on some bio-defense gram negative bacteria therapies fully funded under NIAID research grants. Not sure if funding had been effected by the sequester but the GyrB/ParE preclinical program could be even more clinically important than Ted. No idea when Trius will be able to enter Phase I trials for the gyrase inhibitors but if and when they do this will shoot up big time on spec. We could have a CBST run in the works. Only conjecture at this point and we both know how Holy Grail chases can turn out"
Not sure why I thought GyrB/ParE wide spectrum didn't cover gram negative bacteria, both are mutually inclusive. Perhaps earlier I may have thought Ted covered both. Going by memory, my bad... must be the MJ effect being in this stock too long. One should always check the company website bfr. commenting. My background isn't biochemistry, perhaps I just didn't grasp or forgot this significant aspect of their pipeline potential.
The gram -ve program, if successful, given Tedizolid has been shown to be best in it's class, will make Trius best on the market. Speculation alone on gram negative targeted antibiotics should dble SP once clinical trials commence later this year. Thanxs for the DD update & clarification Kitty. WAY undervalued at current levels.
Golong, sorry for the inaccuracy of my previous comment on gram -ve applications & TSRX's NIAID biodefense program. We need to buy more shares tomorrow bfr Cubist corners the market or terrorists strike..
good call better entry than chasing it anyway. Now pray we hold 777 tomorrow. Prayer meeting at 8pm tonight at Pug Wash Chapel. All critters welcome. Bingo night suspended till we reach 888. Mrs Alfalski will be playing the organ. I'll be play'n mine.
the entire purpose of the GAIN act was to encourage and expedite approval of gram positive antibiotics such as Tedizolid. So far Tedizolid phosphate was shown to be best in it's class and an alternative to linezolid for treating ABSSS. Further indications studies for blood and pneumonia infections will follow later this year. Being a bactericide makes Ted even more effective in killing the bacteria rather than slowing it down as many other antibiotics have in the past encouraging the development of resistant strains. Ted is effective against MRSA.
GyrB/ParE, which are under preclinical program and are targets of the fluoroquinolone (wide spectrum)class of antibacterial agents, such as ciprofloxacin are used to treat gram +ve Streptococcus pneumonia. I don't know of any gram negative agents (bio-terrorism) TRSX is working on to date. But it might be all hush, hush like SIGA. (8=3) Hope this helps.
TSRX looks like the better fit for CBST. The Street's plugging that rumor based on this morning's article. Maybe the OPTR bid is just a divergence to the real deal.